COMP <GO>
PBH vs LLY // PIOTROSKI F-SCORE QUALITY
Prestige Consumer Healthcare Inc. (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: PBH 3
— LLY 10
▲ PIOTROSKI F-SCORE QUALITY LEADER: LLY
LAST: $48.75 (+2.01%) • MKT CAP: $2.31B
piotroski-score
6/9
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
piotroski-score
9/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PBH VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PBH | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 54.70% | 83.64% | -28.94 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 13.80% | 32.36% | -18.56 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 7.0x | 36.4x | -29.42 | PBH | /valuation <GO> |
| Free Cash Flow Yield | 10.67% | 2.30% | +8.37 | PBH | /fcf-yield <GO> |
| Operating Margin | 28.40% | 40.21% | -11.81 | LLY | /operating-margins <GO> |
| Net Profit Margin | 17.50% | 31.90% | -14.40 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | -4.30% | 45.51% | -49.81 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.21 | 9.29 | -7.08 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 6/9 | 9/9 | -3.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.5 | 66.6 | -14.10 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 11.3x | 30.6x | -19.32 | PBH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.31B | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PBH REV | LLY REV | PBH GROSS % | LLY GROSS % | PBH FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.09B | $65.18B | 54.7% | 83.0% | $246.4M | $16.81B |
| FY 2024 | $1.14B | $45.04B | 55.8% | 81.3% | $243.3M | $8.82B |
| FY 2023 | $1.13B | $34.12B | — | 79.3% | $248.9M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PBH // BETA —
LLY // BETA 0.51